Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Abigail Ham

Physician Assistant Florence, SC Physician Assistant

NPI 1528494051 CMS profile 11221597

1702 Freedom Blvd, Florence, SC 29505

Open in the dashboard

General payments

$10,395

573 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Abigail Ham of Florence, SC is reported in the CMS Open Payments database as having received $10,395 across 573 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,269 120
2024 General $3,723 215
2023 General $3,708 204
2022 General $569 25
2021 General $126 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abigail Ham
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Abigail Ham were reported at $2,269. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Abigail Ham Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $126 $132 $37–$438 $132
2022 $569 $155 $48–$522 $149
2023 $3,708 $167 $52–$557 $160
2024 $3,723 $178 $55–$600 $164
2025 $2,269 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Teva Pharmaceuticals USA, Inc. $2,432 117 payments
  2. AbbVie, Inc. $1,276 100 payments
  3. UCB, Inc. $911 48 payments
  4. Neurocrine Biosciences, Inc. $659 40 payments
  5. Novartis Pharmaceuticals Corporation $537 34 payments
  6. Pfizer Inc. $406 28 payments
  7. SK Life Science, Inc. $399 14 payments
  8. TG Therapeutics, Inc. $338 18 payments
  9. Celgene Corporation $224 22 payments
  10. Mallinckrodt Hospital Products Inc. $200 11 payments
  11. Other $3,014 141 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,310 572 payments
  2. Education $85 1 payment
Products named General payments · program years 2021–2025
  1. Austedo XR $1,713 92 payments
  2. INGREZZA $659 40 payments
  3. UBRELVY $604 51 payments
  4. AUSTEDO $597 22 payments
  5. KESIMPTA $494 31 payments
  6. QULIPTA $415 36 payments
  7. BRIUMVI $338 18 payments
  8. Briviact $329 19 payments
  9. NURTEC ODT $308 21 payments
  10. ZAVZPRET $268 17 payments
  11. Other $5,130 277 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

2,768

Median for Physician Assistant: 241

Drug cost

$1,158,758

Median for Physician Assistant: $4,110

Branded share of claims

39.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 16 $132,375
Nurtec Odt Rimegepant Sulfate Brand 83 $130,879
Ubrelvy Ubrogepant Brand 81 $128,001
Fycompa Perampanel Brand 87 $99,108
Austedo Xr Deutetrabenazine Brand 12 $97,318
Ajovy Autoinjector Fremanezumab-Vfrm Brand 103 $86,827
Emgality Pen Galcanezumab-Gnlm Brand 102 $84,864
Aptiom Eslicarbazepine Acetate Brand 41 $57,644
Aimovig Autoinjector Erenumab-Aooe Brand 62 $48,083
Qulipta Atogepant Brand 36 $37,612

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$94,645

Of which drugs: $20,344

Medicare patients

374

Average age 72

Services billed

8,569

245 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 41%
Chronic kidney disease 40%
Depression 33%
Ischemic heart disease 30%
COPD 25%
Heart failure 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 12 5,000 $20,070
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 12 1,300 $129
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 20 104 $70

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 43 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $773
$773 12 —
INGREZZA
  • Neurocrine Biosciences, Inc. $312
$312 16 —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $300
$300 — —
Briviact
  • UCB, Inc. $182
$182 11 —
UBRELVY
  • AbbVie, Inc. $178
$178 81 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 43 with Patron

Records

573 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record